The DOI matches its Crossref record; 153 of the 153 references it cites were found in a registry or an index.
Dupilumab progressively improves systemic and cutaneous abnormalities in patients with atopic dermatitis
Open accessAbstract
Background Dupilumab is an IL-4 receptor α mAb inhibiting signaling of IL-4 and IL-13, key drivers of type 2–driven inflammation, as demonstrated by its efficacy in patients with atopic/allergic diseases. Objective This placebo-controlled, double-blind trial (NCT01979016) evaluated the efficacy, safety, and effects of dupilumab on molecular/cellular lesional and nonlesional skin phenotypes and systemic type 2 biomarkers of patients with moderate-to-severe atopic dermatitis (AD). Methods Skin biopsy specimens and blood were evaluated from 54 patients randomized 1:1 to weekly subcutaneous doses of 200 mg of dupilumab or placebo for 16 weeks. Results Dupilumab (vs placebo) significantly improved clinical signs and symptoms of AD, was well tolerated, and progressively shifted the lesional transcriptome toward a nonlesional phenotype (weeks 4–16). Mean improvements in a meta-analysis–derived AD transcriptome (genes differentially expressed between lesional and nonlesional skin) were 68.8% and 110.8% with dupilumab and −10.5% and 55.0% with placebo (weeks 4 and 16, respectively; P < .001). Dupilumab significantly reduced expression of genes involved in type 2 inflammation ( IL13 , IL31 , CCL17 , CCL18 , and CCL26 ), epidermal hyperplasia (keratin 16 [K16] and MKi67 ), T cells, dendritic cells ( ICOS , CD11c , and CTLA4 ), and T H 17/T H 22 activity ( IL17A , IL-22 , and S100As ) and concurrently increased expression of epidermal differentiation, barrier, and lipid metabolism genes (filaggrin [FLG] , loricrin [LOR] , claudins, and ELOVL3 ). Dupilumab reduced lesional epidermal thickness versus placebo (week 4, P = .001; week 16, P = .0002). Improvements in clinical and histologic measures correlated significantly with modulation of gene expression. Dupilumab also significantly suppressed type 2 serum biomarkers, including CCL17, CCL18, periostin, and total and allergen-specific IgEs. Conclusion Dupilumab-mediated inhibition of IL-4/IL-13 signaling through IL-4 receptor α blockade significantly and progressively improved disease activity, suppressed cellular/molecular cutaneous markers of inflammation and systemic measures of type 2 inflammation, and reversed AD-associated epidermal abnormalities.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Controlling the False Discovery Rate: A Practical and Powerful Approach to Multiple Testing
Benjamini, Y., & Hochberg, Y. (1995) · Journal of the Royal Statistical Society Series B: Statistical Methodology · doi:10.1111/j.2517-6161.1995.tb02031.x · Cited by 109,482
GSVA: gene set variation analysis for microarray and RNA-Seq data
Hänzelmann, S., Castelo, R., & Guinney, J. (2013) · BMC Bioinformatics · doi:10.1186/1471-2105-14-7 · Cited by 15,440
Development of Monocytes, Macrophages, and Dendritic Cells
Geissmann, F., Manz, M. G., Jung, S., Sieweke, M. H., Merad, M., & Ley, K. (2010) · Science · doi:10.1126/science.1178331 · Cited by 3,049
Two Phase 3 Trials of Dupilumab versus Placebo in Atopic Dermatitis
Simpson, E. L., Bieber, T., Guttman-Yassky, E., Beck, L. A., Blauvelt, A., Cork, M. J., Silverberg, J. I., Deleuran, M., Kataoka, Y., Lacour, J.-P., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1610020 · Cited by 2,110 · cited 1×
“It is also the first study to evaluate tissue responses around the time at which most patients have a maximal clinical response to dupilumab, thus allowing correlation of the extent of disease reversal in skin lesions and circulating markers with clinical responses.(25,26) Compared with placebo, dupilumab progressivel…”
BackgroundSelf-citationDupilumab Efficacy and Safety in Moderate-to-Severe Uncontrolled Asthma
Castro, M., Corren, J., Pavord, I. D., Maspero, J., Wenzel, S., Rabe, K. F., Busse, W. W., Ford, L., Sher, L., FitzGerald, J. M., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1804092 · Cited by 1,986
Self-citationEndogenous Antimicrobial Peptides and Skin Infections in Atopic Dermatitis
Ong, P. Y., Ohtake, T., Brandt, C., Strickland, I., Boguniewicz, M., Ganz, T., Gallo, R. L., & Leung, D. Y. M. (2002) · New England Journal of Medicine · doi:10.1056/nejmoa021481 · Cited by 1,960
A Model-Based Background Adjustment for Oligonucleotide Expression Arrays
Wu, Z., Irizarry, R. A., Gentleman, R., Martinez-Murillo, F., & Spencer, F. (2004) · Journal of the American Statistical Association · doi:10.1198/016214504000000683 · Cited by 1,716
Dupilumab Treatment in Adults with Moderate-to-Severe Atopic Dermatitis
Beck, L. A., Thaçi, D., Hamilton, J. D., Graham, N. M., Bieber, T., Rocklin, R., Ming, J. E., Ren, H., Kao, R., Simpson, E., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1314768 · Cited by 1,421
Self-citationDupilumab in Persistent Asthma with Elevated Eosinophil Levels
Wenzel, S., Ford, L., Pearlman, D., Spector, S., Sher, L., Skobieranda, F., Wang, L., Kirkesseli, S., Rocklin, R., Bock, B., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1304048 · Cited by 1,320
Self-citationBlauvelt, A., de Bruin-Weller, M., Gooderham, M., Cather, J. C., Weisman, J., Pariser, D., Simpson, E. L., Papp, K. A., Hong, H. C.-H., Rubel, D., et al. (2017) · The Lancet · doi:10.1016/s0140-6736(17)31191-1 · Cited by 1,261
Self-citationEfficacy and Safety of Dupilumab in Glucocorticoid-Dependent Severe Asthma
Rabe, K. F., Nair, P., Brusselle, G., Maspero, J. F., Castro, M., Sher, L., Zhu, H., Hamilton, J. D., Swanson, B. N., Khan, A., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1804093 · Cited by 1,184
Self-citationCytokine modulation of atopic dermatitis filaggrin skin expression
Howell, M. D., Kim, B. E., Gao, P., Grant, A. V., Boguniewicz, M., DeBenedetto, A., Schneider, L., Beck, L. A., Barnes, K. C., & Leung, D. Y. M. (2007) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2007.04.031 · Cited by 1,084
Wenzel, S., Castro, M., Corren, J., Maspero, J., Wang, L., Zhang, B., Pirozzi, G., Sutherland, E. R., Evans, R. R., Joish, V. N., et al. (2016) · The Lancet · doi:10.1016/s0140-6736(16)30307-5 · Cited by 985
Self-citationGittler, J. K., Shemer, A., Suárez-Fariñas, M., Fuentes-Duculan, J., Gulewicz, K. J., Wang, C. Q. F., Mitsui, H., Cardinale, I., de Guzman Strong, C., Krueger, J. G., et al. (2012) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2012.07.012 · Cited by 981
Self-citationBoniface, K., Bernard, F.-X., Garcia, M., Gurney, A. L., Lecron, J.-C., & Morel, F. (2005) · The Journal of Immunology · doi:10.4049/jimmunol.174.6.3695 · Cited by 864
Phase 3 Trials of Ixekizumab in Moderate-to-Severe Plaque Psoriasis
Gordon, K. B., Blauvelt, A., Papp, K. A., Langley, R. G., Luger, T., Ohtsuki, M., Reich, K., Amato, D., Ball, S. G., Braun, D. K., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1512711 · Cited by 848
Phase 3 Studies Comparing Brodalumab with Ustekinumab in Psoriasis
Lebwohl, M., Strober, B., Menter, A., Gordon, K., Weglowska, J., Puig, L., Papp, K., Spelman, L., Toth, D., Kerdel, F., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1503824 · Cited by 828
Self-citationNograles, K. E., Zaba, L. C., Guttman-Yassky, E., Fuentes-Duculan, J., Suárez-Fariñas, M., Cardinale, I., Khatcherian, A., Gonzalez, J., Pierson, K. C., White, T. R., et al. (2008) · British Journal of Dermatology · doi:10.1111/j.1365-2133.2008.08769.x · Cited by 804
Self-citationBachert, C., Mannent, L., Naclerio, R. M., Mullol, J., Ferguson, B. J., Gevaert, P., Hellings, P., Jiao, L., Wang, L., Evans, R. R., et al. (2016) · JAMA · doi:10.1001/jama.2015.19330 · Cited by 794 · cited 1×
“Of note, a dupilumab-associated increase in conjunctivitis has not been seen in studies of dupilumab in patients with other indications, such as asthma(29,30,33,34) and chronic rhinosinusitis with nasal polyposis.(31) The parallel, longer-term tissue reversibility of key AD epidermal and immune features with dupilumab…”
BackgroundSelf-citationNomura, I., Goleva, E., Howell, M. D., Hamid, Q. A., Ong, P. Y., Hall, C. F., Darst, M. A., Gao, B., Boguniewicz, M., Travers, J. B., et al. (2003) · The Journal of Immunology · doi:10.4049/jimmunol.171.6.3262 · Cited by 731
The burden of atopic dermatitis: summary of a report for the National Eczema Association.
Drucker, A. M., Wang, A. R., Li, W.-Q., Sevetson, E., Block, J. K., & Qureshi, A. A. (2017) · Journal of Investigative Dermatology · doi:10.1016/j.jid.2016.07.012 · Cited by 720
Chiricozzi, A., Guttman-Yassky, E., Suárez-Fariñas, M., Nograles, K. E., Tian, S., Cardinale, I., Chimenti, S., & Krueger, J. G. (2011) · Journal of Investigative Dermatology · doi:10.1038/jid.2010.340 · Cited by 686
Self-citationAmelioration of epidermal hyperplasia by TNF inhibition is associated with reduced Th17 responses
Zaba, L. C., Cardinale, I., Gilleaudeau, P., Sullivan-Whalen, M., Suárez-Fariñas, M., Fuentes-Duculan, J., Novitskaya, I., Khatcherian, A., Bluth, M. J., Lowes, M. A., et al. (2007) · The Journal of Experimental Medicine · doi:10.1084/jem.20071094 · Cited by 676
Self-citationHuman Inflammatory Dendritic Cells Induce Th17 Cell Differentiation
Segura, E., Touzot, M., Bohineust, A., Cappuccio, A., Chiocchia, G., Hosmalin, A., Dalod, M., Soumelis, V., & Amigorena, S. (2013) · Immunity · doi:10.1016/j.immuni.2012.10.018 · Cited by 676
Possible Pathogenic Role of Th17 Cells for Atopic Dermatitis
Koga, C., Kabashima, K., Shiraishi, N., Kobayashi, M., & Tokura, Y. (2008) · Journal of Investigative Dermatology · doi:10.1038/jid.2008.111 · Cited by 671
IL-17 is essential for host defense against cutaneous Staphylococcus aureus infection in mice
Cho, J. S., Pietras, E. M., Garcia, N. C., Ramos, R. I., Farzam, D. M., Monroe, H. R., Magorien, J. E., Blauvelt, A., Kolls, J. K., Cheung, A. L., et al. (2010) · Journal of Clinical Investigation · doi:10.1172/jci40891 · Cited by 658
Noda, S., Suárez-Fariñas, M., Ungar, B., Kim, S. J., de Guzman Strong, C., Xu, H., Peng, X., Estrada, Y. D., Nakajima, S., Honda, T., et al. (2015) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2015.08.015 · Cited by 657
Self-citationTh2 Cytokines and Atopic Dermatitis
B. Brandt, E. (2011) · Journal of Clinical & Cellular Immunology · doi:10.4172/2155-9899.1000110 · Cited by 655
The immunology of atopic dermatitis and its reversibility with broad-spectrum and targeted therapies
Brunner, P. M., Guttman-Yassky, E., & Leung, D. Y. M. (2017) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2017.01.011 · Cited by 642
Self-citationNograles, K. E., Zaba, L. C., Shemer, A., Fuentes-Duculan, J., Cardinale, I., Kikuchi, T., Ramon, M., Bergman, R., Krueger, J. G., & Guttman-Yassky, E. (2009) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2009.03.041 · Cited by 627 · cited 1×
“Although dupilumab’s effects have proved that the type 2 pathway is central to AD pathogenesis, previous studies have shown that the TH22 and TH17 pathways can also play contributory roles in the AD phenotype and its epidermal pathology.(1,3-5,7,20,51,53,129,130) However, consistent robust efficacy in patients with AD…”
ResultSelf-citationthe EArly Genetics and Lifecourse Epidemiology (EAGLE) Eczema Consortium (2015) · Nature Genetics · doi:10.1038/ng.3424 · Cited by 621
Anti–Interleukin-31 Receptor A Antibody for Atopic Dermatitis
Ruzicka, T., Hanifin, J. M., Furue, M., Pulka, G., Mlynarczyk, I., Wollenberg, A., Galus, R., Etoh, T., Mihara, R., Yoshida, H., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1606490 · Cited by 592
Kakinuma, T., Nakamura, K., Wakugawa, M., Mitsui, H., Tada, Y., Saeki, H., Torii, H., Asahina, A., Onai, N., Matsushima, K., et al. (2001) · Journal of Allergy and Clinical Immunology · doi:10.1067/mai.2001.113237 · Cited by 575
Thaçi, D., Simpson, E. L., Beck, L. A., Bieber, T., Blauvelt, A., Papp, K., Soong, W., Worm, M., Szepietowski, J. C., Sofen, H., et al. (2016) · The Lancet · doi:10.1016/s0140-6736(15)00388-8 · Cited by 572
Self-citationLoricrin and involucrin expression is down-regulated by Th2 cytokines through STAT-6
Kim, B. E., Leung, D. Y. M., Boguniewicz, M., & Howell, M. D. (2008) · Clinical Immunology · doi:10.1016/j.clim.2007.11.006 · Cited by 538
The IL-23/T17 pathogenic axis in psoriasis is amplified by keratinocyte responses
Lowes, M. A., Russell, C. B., Martin, D. A., Towne, J. E., & Krueger, J. G. (2013) · Trends in Immunology · doi:10.1016/j.it.2012.11.005 · Cited by 537
Self-citationSa, S. M., Valdez, P. A., Wu, J., Jung, K., Zhong, F., Hall, L., Kasman, I., Winer, J., Modrusan, Z., Danilenko, D. M., et al. (2007) · The Journal of Immunology · doi:10.4049/jimmunol.178.4.2229 · Cited by 514
Suárez-Fariñas, M., Dhingra, N., Gittler, J., Shemer, A., Cardinale, I., de Guzman Strong, C., Krueger, J. G., & Guttman-Yassky, E. (2013) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2013.04.046 · Cited by 483
Self-citationde Bruin-Weller, M., Thaçi, D., Smith, C. H., Reich, K., Cork, M. J., Radin, A., Zhang, Q., Akinlade, B., Gadkari, A., Eckert, L., et al. (2018) · British Journal of Dermatology · doi:10.1111/bjd.16156 · Cited by 479
Self-citationDeciphering the complexities of atopic dermatitis: Shifting paradigms in treatment approaches
Leung, D. Y. M., & Guttman-Yassky, E. (2014) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2014.08.008 · Cited by 474
Self-citationCytokine modulation of atopic dermatitis filaggrin skin expression
Howell, M. D., Kim, B. E., Gao, P., Grant, A. V., Boguniewicz, M., DeBenedetto, A., Schneider, L., Beck, L. A., Barnes, K. C., & Leung, D. Y. M. (2009) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2009.07.012 · Cited by 473
Hamilton, J. D., Suárez-Fariñas, M., Dhingra, N., Cardinale, I., Li, X., Kostic, A., Ming, J. E., Radin, A. R., Krueger, J. G., Graham, N., et al. (2014) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2014.10.013 · Cited by 469
Self-citationSuárez-Fariñas, M., Tintle, S. J., Shemer, A., Chiricozzi, A., Nograles, K., Cardinale, I., Duan, S., Bowcock, A. M., Krueger, J. G., & Guttman-Yassky, E. (2011) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2010.12.1124 · Cited by 464
Self-citationMurphy, A. J., Macdonald, L. E., Stevens, S., Karow, M., Dore, A. T., Pobursky, K., Huang, T. T., Poueymirou, W. T., Esau, L., Meola, M., et al. (2014) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1324022111 · Cited by 455
Self-citationEarly-onset pediatric atopic dermatitis is TH2 but also TH17 polarized in skin
Esaki, H., Brunner, P. M., Renert-Yuval, Y., Czarnowicki, T., Huynh, T., Tran, G., Lyon, S., Rodriguez, G., Immaneni, S., Johnson, D. B., et al. (2016) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2016.07.013 · Cited by 428
Self-citationPrecise and in situ genetic humanization of 6 Mb of mouse immunoglobulin genes
Macdonald, L. E., Karow, M., Stevens, S., Auerbach, W., Poueymirou, W. T., Yasenchak, J., Frendewey, D., Valenzuela, D. M., Giallourakis, C. C., Alt, F. W., et al. (2014) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1323896111 · Cited by 391
Self-citationIL-17A is essential for cell activation and inflammatory gene circuits in subjects with psoriasis
Krueger, J. G., Fretzin, S., Suárez-Fariñas, M., Haslett, P. A., Phipps, K. M., Cameron, G. S., McColm, J., Katcherian, A., Cueto, I., White, T., et al. (2012) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2012.04.024 · Cited by 383
Self-citationIncreasing Comorbidities Suggest that Atopic Dermatitis Is a Systemic Disorder
Brunner, P. M., Silverberg, J. I., Guttman-Yassky, E., Paller, A. S., Kabashima, K., Amagai, M., Luger, T. A., Deleuran, M., Werfel, T., Eyerich, K., et al. (2017) · Journal of Investigative Dermatology · doi:10.1016/j.jid.2016.08.022 · Cited by 377
Self-citationSuper-enhancers delineate disease-associated regulatory nodes in T cells
Vahedi, G., Kanno, Y., Furumoto, Y., Jiang, K., Parker, S. C. J., Erdos, M. R., Davis, S. R., Roychoudhuri, R., Restifo, N. P., Gadina, M., et al. (2015) · Nature · doi:10.1038/nature14154 · Cited by 374
A Population-Based Survey of Eczema Prevalence in the United States
Hanifin, J. M., & Reed, M. L. (2007) · Dermatitis · doi:10.2310/6620.2007.06034 · Cited by 349
Guttman-Yassky, E., Brunner, P. M., Neumann, A. U., Khattri, S., Pavel, A. B., Malik, K., Singer, G. K., Baum, D., Gilleaudeau, P., Sullivan-Whalen, M., et al. (2018) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2018.01.016 · Cited by 343 · cited 2×
“Targeting other pathways, such as the TH17/IL-23 or TH22 pathways, with ustekinumab (anti–IL-12/23 p40) or fezakinumab/ILV-094 (anti–IL-22) has been less efficacious relative to what has been observed in dupilumab AD trials to date.(44,45) Scientific evidence supports the view of AD as a systemic immune-driven disease…”
ResultSelf-citationOldhoff, J. M., Darsow, U., Werfel, T., Katzer, K., Wulf, A., Laifaoui, J., Hijnen, D. J., Plötz, S., Knol, E. F., Kapp, A., et al. (2005) · Allergy · doi:10.1111/j.1398-9995.2005.00791.x · Cited by 339
Low Expression of the IL-23/Th17 Pathway in Atopic Dermatitis Compared to Psoriasis
Guttman-Yassky, E., Lowes, M. A., Fuentes-Duculan, J., Zaba, L. C., Cardinale, I., Nograles, K. E., Khatcherian, A., Novitskaya, I., Carucci, J. A., Bergman, R., et al. (2008) · The Journal of Immunology · doi:10.4049/jimmunol.181.10.7420 · Cited by 331
Self-citationSimpson, E. L., Flohr, C., Eichenfield, L. F., Bieber, T., Sofen, H., Taïeb, A., Owen, R., Putnam, W., Castro, M., DeBusk, K., et al. (2018) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2018.01.017 · Cited by 331
Danso, M. O., van Drongelen, V., Mulder, A., van Esch, J., Scott, H., van Smeden, J., El Ghalbzouri, A., & Bouwstra, J. A. (2014) · Journal of Investigative Dermatology · doi:10.1038/jid.2014.83 · Cited by 330
Huss, K., Adkinson, N. F., Eggleston, P. A., Dawson, C., Van Natta, M. L., & Hamilton, R. G. (2001) · Journal of Allergy and Clinical Immunology · doi:10.1067/mai.2001.111146 · Cited by 315
Guttman-Yassky, E., Nograles, K. E., & Krueger, J. G. (2011) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2011.01.054 · Cited by 314
Self-citationAn update on the genetics of atopic dermatitis: Scratching the surface in 2009
Barnes, K. C. (2010) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2009.11.008 · Cited by 309
A Phase 2 Trial of Guselkumab versus Adalimumab for Plaque Psoriasis
Gordon, K. B., Duffin, K. C., Bissonnette, R., Prinz, J. C., Wasfi, Y., Li, S., Shen, Y.-K., Szapary, P., Randazzo, B., & Reich, K. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1501646 · Cited by 306
Self-citationDhingra, N., Shemer, A., Correa da Rosa, J., Rozenblit, M., Fuentes-Duculan, J., Gittler, J. K., Finney, R., Czarnowicki, T., Zheng, X., Xu, H., et al. (2014) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2014.03.009 · Cited by 305
Self-citationZaba, L. C., Suárez-Fariñas, M., Fuentes-Duculan, J., Nograles, K. E., Guttman-Yassky, E., Cardinale, I., Lowes, M. A., & Krueger, J. G. (2009) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2009.08.046 · Cited by 303
Self-citationSimpson, E. L., Bieber, T., Eckert, L., Wu, R., Ardeleanu, M., Graham, N. M. H., Pirozzi, G., & Mastey, V. (2016) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2015.10.043 · Cited by 302
Self-citationZhang, A., & Silverberg, J. I. (2015) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2014.12.013 · Cited by 287
Self-citationHijnen, D., de Bruin-Weller, M., Oosting, B., Lebre, C., de Jong, E., Bruijnzeel-Koomen, C., & Knol, E. (2004) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2003.12.007 · Cited by 269
Broad defects in epidermal cornification in atopic dermatitis identified through genomic analysis
Guttman-Yassky, E., Suárez-Fariñas, M., Chiricozzi, A., Nograles, K. E., Shemer, A., Fuentes-Duculan, J., Cardinale, I., Lin, P., Bergman, R., Bowcock, A. M., et al. (2009) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2009.09.031 · Cited by 268
Self-citationSuárez-Fariñas, M., Ungar, B., Correa da Rosa, J., Ewald, D. A., Rozenblit, M., Gonzalez, J., Xu, H., Zheng, X., Peng, X., Estrada, Y. D., et al. (2015) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2015.03.003 · Cited by 268
Self-citationSuárez-Fariñas, M., Ungar, B., Noda, S., Shroff, A., Mansouri, Y., Fuentes-Duculan, J., Czernik, A., Zheng, X., Estrada, Y. D., Xu, H., et al. (2015) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2015.06.032 · Cited by 262
Self-citationBrunner, P. M., Suárez-Fariñas, M., He, H., Malik, K., Wen, H.-C., Gonzalez, J., Chan, T. C.-C., Estrada, Y., Zheng, X., Khattri, S., et al. (2017) · Scientific Reports · doi:10.1038/s41598-017-09207-z · Cited by 260
Self-citationKrueger, J. G., Ferris, L. K., Menter, A., Wagner, F., White, A., Visvanathan, S., Lalovic, B., Aslanyan, S., Wang, E. E. L., Hall, D., et al. (2015) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2015.01.018 · Cited by 256
Self-citationGenetic and epigenetic studies of atopic dermatitis
Bin, L., & Leung, D. Y. M. (2016) · Allergy, Asthma & Clinical Immunology · doi:10.1186/s13223-016-0158-5 · Cited by 242
The cutaneous innate immune response in patients with atopic dermatitis
Kuo, I.-H., Yoshida, T., De Benedetto, A., & Beck, L. A. (2013) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2012.12.1563 · Cited by 231
Th2 Cytokines Act on S100/A11 to Downregulate Keratinocyte Differentiation
Howell, M. D., Fairchild, H. R., Kim, B. E., Bin, L., Boguniewicz, M., Redzic, J. S., Hansen, K. C., & Leung, D. Y. M. (2008) · Journal of Investigative Dermatology · doi:10.1038/jid.2008.74 · Cited by 224
Biomarkers for atopic dermatitis: a systematic review and meta-analysis
Thijs, J., Krastev, T., Weidinger, S., Buckens, C. F., de Bruin-Weller, M., Bruijnzeel-Koomen, C., Flohr, C., & Hijnen, D. (2015) · Current Opinion in Allergy & Clinical Immunology · doi:10.1097/aci.0000000000000198 · Cited by 224
Tintle, S., Shemer, A., Suárez-Fariñas, M., Fujita, H., Gilleaudeau, P., Sullivan-Whalen, M., Johnson-Huang, L., Chiricozzi, A., Cardinale, I., Duan, S., et al. (2011) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2011.05.042 · Cited by 220
Self-citationEsaki, H., Ewald, D. A., Ungar, B., Rozenblit, M., Zheng, X., Xu, H., Estrada, Y. D., Peng, X., Mitsui, H., Litman, T., et al. (2015) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2014.10.037 · Cited by 219
Self-citationTwo Phase 3 Trials of Dupilumab versus Placebo in Atopic Dermatitis
(2017) · New England Journal of Medicine · doi:10.1056/nejmc1700366 · Cited by 219
Efficacy and safety of ustekinumab treatment in adults with moderate‐to‐severe atopic dermatitis
Khattri, S., Brunner, P. M., Garcet, S., Finney, R., Cohen, S. R., Oliva, M., Dutt, R., Fuentes‐Duculan, J., Zheng, X., Li, X., et al. (2017) · Experimental Dermatology · doi:10.1111/exd.13112 · Cited by 214
Self-citationAn Integrated Model of Atopic Dermatitis Biomarkers Highlights the Systemic Nature of the Disease
Ungar, B., Garcet, S., Gonzalez, J., Dhingra, N., Correa da Rosa, J., Shemer, A., Krueger, J. G., Suarez-Farinas, M., & Guttman-Yassky, E. (2017) · Journal of Investigative Dermatology · doi:10.1016/j.jid.2016.09.037 · Cited by 213
Self-citationCzarnowicki, T., Esaki, H., Gonzalez, J., Malajian, D., Shemer, A., Noda, S., Talasila, S., Berry, A., Gray, J., Becker, L., et al. (2015) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2015.05.049 · Cited by 210
Self-citationSilverberg, J. I. (2015) · Allergy · doi:10.1111/all.12685 · Cited by 207
Self-citationThe translational revolution and use of biologics in patients with inflammatory skin diseases
Noda, S., Krueger, J. G., & Guttman-Yassky, E. (2015) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2014.11.015 · Cited by 198
Self-citationHeil, P. M., Maurer, D., Klein, B., Hultsch, T., & Stingl, G. (2010) · JDDG: Journal der Deutschen Dermatologischen Gesellschaft · doi:10.1111/j.1610-0387.2010.07497.x · Cited by 197
The role of IL-22 and Th22 cells in human skin diseases
Fujita, H. (2013) · Journal of Dermatological Science · doi:10.1016/j.jdermsci.2013.04.028 · Cited by 197
Baurecht, H., Hotze, M., Brand, S., Büning, C., Cormican, P., Corvin, A., Ellinghaus, D., Ellinghaus, E., Esparza-Gordillo, J., Fölster-Holst, R., et al. (2015) · The American Journal of Human Genetics · doi:10.1016/j.ajhg.2014.12.004 · Cited by 193
Wolk, K., Witte, E., Warszawska, K., Schulze‐Tanzil, G., Witte, K., Philipp, S., Kunz, S., Döcke, W., Asadullah, K., Volk, H., et al. (2009) · European Journal of Immunology · doi:10.1002/eji.200939687 · Cited by 181
Khattri, S., Shemer, A., Rozenblit, M., Dhingra, N., Czarnowicki, T., Finney, R., Gilleaudeau, P., Sullivan-Whalen, M., Zheng, X., Xu, H., et al. (2014) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2014.03.003 · Cited by 180
Self-citationCho, S.-H., Strickland, I., Tomkinson, A., Fehringer, A. P., Gelfand, E. W., & Leung, D. Y. M. (2001) · Journal of Investigative Dermatology · doi:10.1046/j.0022-202x.2001.01331.x · Cited by 178
Highly Effective New Treatments for Psoriasis Target the IL-23/Type 17 T Cell Autoimmune Axis
Kim, J., & Krueger, J. G. (2017) · Annual Review of Medicine · doi:10.1146/annurev-med-042915-103905 · Cited by 174
Self-citationHaider, A. S., Lowes, M. A., Suárez-Fariñas, M., Zaba, L. C., Cardinale, I., Khatcherian, A., Novitskaya, I., Wittkowski, K. M., & Krueger, J. G. (2008) · The Journal of Immunology · doi:10.4049/jimmunol.180.3.1913 · Cited by 173
Self-citationFailure of omalizumab for treatment of severe adult atopic dermatitis
Krathen, R. A., & Hsu, S. (2005) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2005.02.014 · Cited by 172
IL-17A as an Inducer for Th2 Immune Responses in Murine Atopic Dermatitis Models
Nakajima, S., Kitoh, A., Egawa, G., Natsuaki, Y., Nakamizo, S., Moniaga, C. S., Otsuka, A., Honda, T., Hanakawa, S., Amano, W., et al. (2014) · Journal of Investigative Dermatology · doi:10.1038/jid.2014.51 · Cited by 169
Jahnz‐Rozyk, K., Targowski, T., Paluchowska, E., Owczarek, W., & Kucharczyk, A. (2005) · Allergy · doi:10.1111/j.1398-9995.2005.00774.x · Cited by 168
Galbraith, G. M. P. (2009) · Yearbook of Dermatology and Dermatologic Surgery · doi:10.1016/s0093-3619(09)79289-5 · Cited by 167
Ewald, D. A., Malajian, D., Krueger, J. G., Workman, C. T., Wang, T., Tian, S., Litman, T., Guttman-Yassky, E., & Suárez-Fariñas, M. (2015) · BMC Medical Genomics · doi:10.1186/s12920-015-0133-x · Cited by 166
Self-citationChronic rhinosinusitis and asthma: novel understanding of the role of IgE ‘above atopy’
Bachert, C., & Zhang, N. (2012) · Journal of Internal Medicine · doi:10.1111/j.1365-2796.2012.02559.x · Cited by 164
Thijs, J. L., Strickland, I., Bruijnzeel-Koomen, C. A. F. M., Nierkens, S., Giovannone, B., Csomor, E., Sellman, B. R., Mustelin, T., Sleeman, M. A., de Bruin-Weller, M. S., et al. (2017) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2017.03.023 · Cited by 163
Simpson, E. L., Gadkari, A., Worm, M., Soong, W., Blauvelt, A., Eckert, L., Wu, R., Ardeleanu, M., Graham, N. M. H., Pirozzi, G., et al. (2016) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2016.04.054 · Cited by 160
Self-citationIyengar, S. R., Hoyte, E. G., Loza, A., Bonaccorso, S., Chiang, D. S., Umetsu, D. T., & Nadeau, K. C. (2013) · International Archives of Allergy and Immunology · doi:10.1159/000350486 · Cited by 159
Yuki, T., Tobiishi, M., Kusaka-Kikushima, A., Ota, Y., & TOKURA, Y. (2016) · PLoS ONE · doi:10.1371/journal.pone.0161759 · Cited by 158
Rabeony, H., Petit-Paris, I., Garnier, J., Barrault, C., Pedretti, N., Guilloteau, K., Jégou, J., Guillet, G., Huguier, V., Lecron, J., et al. (2014) · PLoS ONE · doi:10.1371/journal.pone.0101937 · Cited by 156
Kisich, K. O., Howell, M. D., Boguniewicz, M., Heizer, H. R., Watson, N. U., & Leung, D. Y. M. (2007) · Journal of Investigative Dermatology · doi:10.1038/sj.jid.5700861 · Cited by 150
Krueger, J. G., Clark, J. D., Suárez‐Fariñas, M., Fuentes‐Duculan, J., Cueto, I., Wang, C. Q. F., Tan, H., Wolk, R. A., Rottinghaus, S. T., Whitley, M. Z., et al. (2016) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2015.12.1318 · Cited by 142
Self-citationHoffjan, S., & Stemmler, S. (2007) · British Journal of Dermatology · doi:10.1111/j.1365-2133.2007.07999.x · Cited by 135
Whiteley, J., Emir, B., Seitzman, R., & Makinson, G. (2016) · Current Medical Research and Opinion · doi:10.1080/03007995.2016.1195733 · Cited by 132
Increased Prevalence of Coronary Artery Disease in Severe Psoriasis and Severe Atopic Dermatitis
Hjuler, K. F., Bøttcher, M., Vestergaard, C., Deleuran, M. S., Raaby, L., Bøtker, H. E., Iversen, L., & Kragballe, K. (2015) · The American Journal of Medicine · doi:10.1016/j.amjmed.2015.05.041 · Cited by 130
Czarnowicki, T., Gonzalez, J., Bonifacio, K. M., Shemer, A., Xiangyu, P., Kunjravia, N., Malajian, D., Fuentes‐Duculan, J., Esaki, H., Noda, S., et al. (2015) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2015.08.027 · Cited by 126
Self-citationTsuda, K., Yamanaka, K., Kitagawa, H., Akeda, T., Naka, M., Niwa, K., Nakanishi, T., Kakeda, M., Gabazza, E. C., & Mizutani, H. (2012) · PLoS ONE · doi:10.1371/journal.pone.0031465 · Cited by 126
Periostin levels correlate with disease severity and chronicity in patients with atopic dermatitis
Kou, K., Okawa, T., Yamaguchi, Y., Ono, J., Inoue, Y., Kohno, M., Matsukura, S., Kambara, T., Ohta, S., Izuhara, K., et al. (2014) · British Journal of Dermatology · doi:10.1111/bjd.12943 · Cited by 125
New pathogenic and therapeutic paradigms in atopic dermatitis
Malajian, D., & Guttman‐Yassky, E. (2014) · Cytokine · doi:10.1016/j.cyto.2014.11.023 · Cited by 119
Self-citationNew era of biologic therapeutics in atopic dermatitis
Guttman‐Yassky, E., Dhingra, N., & Leung, D. Y. M. (2013) · Expert Opinion on Biological Therapy · doi:10.1517/14712598.2013.758708 · Cited by 116
Self-citationGambichler, T., Othlinghaus, N., Tomi, N. S., Holland‐Letz, T., Boms, S., Skrygan, M., Altmeyer, P. J., & Kreuter, A. (2008) · British Journal of Dermatology · doi:10.1111/j.1365-2133.2008.08984.x · Cited by 115
Association between atopic dermatitis and obesity in adulthood
Silverberg, J. I., Silverberg, N. B., & Lee-Wong, M. F. (2011) · British Journal of Dermatology · doi:10.1111/j.1365-2133.2011.10694.x · Cited by 114
Self-citationOrtiz, R. A., & Barnes, K. C. (2014) · Immunology and Allergy Clinics of North America · doi:10.1016/j.iac.2014.09.014 · Cited by 112
Benedetto, A. D., Slifka, M. K., Rafaels, N. M., Kuo, I., Georas, S. N., Boguniewicz, M., Hata, T. R., Schneider, L. C., Hanifin, J. M., Gallo, R. L., et al. (2011) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2011.02.014 · Cited by 110
Brandt, C., Pavlovic, V., Radbruch, A., Worm, M., & Baumgrass, R. (2009) · Allergy · doi:10.1111/j.1398-9995.2009.02054.x · Cited by 109
Strong, C. D. G., Conlan, S., Deming, C., Cheng, J., Sears, K. E., & Segre, J. A. (2010) · Human Molecular Genetics · doi:10.1093/hmg/ddq019 · Cited by 104
Genome‐wide association studies of atopic dermatitis
Tamari, M., & Hirota, T. (2014) · The Journal of Dermatology · doi:10.1111/1346-8138.12321 · Cited by 100
Systemic therapy for atopic dermatitis
Simon, D., & Bieber, T. R. M. (2013) · Allergy · doi:10.1111/all.12339 · Cited by 97
The Financial and Emotional Impact of Atopic Dermatitis on Children and Their Families
Filanovsky, M. G., Pootongkam, S., Tamburro, J. E., Smith, M. C., Ganocy, S. J., & Nedorost, S. T. (2015) · The Journal of Pediatrics · doi:10.1016/j.jpeds.2015.10.077 · Cited by 95
Drug Evaluation Review: Dupilumab in Atopic Dermatitis
Hamilton, J. D., Ungar, B., & Guttman‐Yassky, E. (2015) · Immunotherapy · doi:10.2217/imt.15.69 · Cited by 95
Self-citationNovak, N., & Leung, D. Y. M. (2011) · Current Opinion in Immunology · doi:10.1016/j.coi.2011.09.007 · Cited by 94
IgE Sensitization Profiles Differ between Adult Patients with Severe and Moderate Atopic Dermatitis
Mittermann, I., Wikberg, G., Johansson, C., Lupinek, C., Lundeberg, L., Crameri, R., Valenta, R., & Scheynius, A. (2016) · PLoS ONE · doi:10.1371/journal.pone.0156077 · Cited by 93
Nonlesional atopic dermatitis skin shares similar T‐cell clones with lesional tissues
Brunner, P. M., Emerson, R., Tipton, C. M., Garcet, S., Khattri, S., Coats, I., Krueger, J. G., & Guttman‐Yassky, E. (2017) · Allergy · doi:10.1111/all.13223 · Cited by 91
Self-citationSkin-homing and systemic T-cell subsets show higher activation in atopic dermatitis versus psoriasis
Czarnowicki, T., Malajian, D., Shemer, A., Fuentes‐Duculan, J., Gonzalez, J., Suárez‐Fariñas, M., Krueger, J. G., & Guttman‐Yassky, E. (2015) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2015.03.032 · Cited by 85
Self-citationImmunomodulatory effects of cyclosporin A on human peripheral blood dendritic cell subsets
Tajima, K., Amakawa, R., Ito, T., Miyaji, M., Takebayashi, M., & Fukuhara, S. (2003) · Immunology · doi:10.1046/j.1365-2567.2003.01585.x · Cited by 81
Systemic therapy of atopic dermatitis
Bußmann, C., & Novak, N. (2017) · Allergologie select · doi:10.5414/alx01285e · Cited by 80
Izuhara, K., Arima, K., & Yasunaga, S. (2002) · Current Drug Targets - Inflammation & Allergy · doi:10.2174/1568010023344661 · Cited by 78
Brunner, P. M., Khattri, S., Garcet, S., Finney, R., Oliva, M., Dutt, R., Fuentes‐Duculan, J., Zheng, X., Li, X., Bonifacio, K. M., et al. (2016) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2015.12.1323 · Cited by 75
Self-citationGuttman‐Yassky, E., & Krueger, J. G. (2007) · British Journal of Dermatology · doi:10.1111/j.1365-2133.2007.08135.x · Cited by 72
Self-citationHarshlight: a "corrective make-up" program for microarray chips
Suárez‐Fariñas, M., Pellegrino, M., Wittkowski, K. M., & Magnasco, M. O. (2005) · BMC Bioinformatics · doi:10.1186/1471-2105-6-294 · Cited by 70
Self-citationBao, L., Shi, V. Y., & Chan, L. S. (2012) · Cytokine · doi:10.1016/j.cyto.2012.10.031 · Cited by 69
Swindell, W. R., Johnston, A. W. B., Xing, X., Voorhees, J. J., Elder, J. T., & Gudjonsson, J. E. (2013) · PLoS ONE · doi:10.1371/journal.pone.0079253 · Cited by 67
House dust mites as potential carriers for IgE sensitization to bacterial antigens
Dzoro, S., Mittermann, I., Resch, Y., Vrtala, S., Nehr, M., Hirschl, A. M., Wikberg, G., Lundeberg, L., Johansson, C., Scheynius, A., et al. (2017) · Allergy · doi:10.1111/all.13260 · Cited by 63
Fukuie, T., Hirakawa, S., Narita, M., Nomura, I., Matsumoto, K., TOKURA, Y., & Ohya, Y. (2016) · The Journal of Dermatology · doi:10.1111/1346-8138.13408 · Cited by 59
Oldhoff, J., Darsow, U. G., Werfel, T., Bihari, I. C., Katzer, K., Laifaoui, J., Plötz, S. G., Kapp, A., Knol, E. F., Bruijnzeel-Koomen, C. A. F. M., et al. (2006) · International Archives of Allergy and Immunology · doi:10.1159/000095299 · Cited by 58
Mulcahy, M. E., Leech, J. M., Renauld, J.-C., Mills, K. H., & McLoughlin, R. M. (2016) · Mucosal Immunology · doi:10.1038/mi.2016.24 · Cited by 58
Kattan, J. D., Sicherer, S. H., & Sampson, H. A. (2014) · The Journal of Allergy and Clinical Immunology In Practice · doi:10.1016/j.jaip.2014.03.013 · Cited by 56
Current and Future Biomarkers in Atopic Dermatitis
Thijs, J. L., de Bruin-Weller, M. S., & Hijnen, D. (2016) · Immunology and Allergy Clinics of North America · doi:10.1016/j.iac.2016.08.008 · Cited by 49
Review of Systemic Treatment Options for Adult Atopic Dermatitis
Gooderham, M., Lynde, C. W., Papp, K. A., Bourcier, M., Guenther, L., Gulliver, W. P. F., Hong, C.-H., Poulin, Y. P., Sussman, G. L., & Vender, R. B. (2016) · Journal of Cutaneous Medicine and Surgery · doi:10.1177/1203475416670364 · Cited by 47
Clinical implications of new mechanistic insights into atopic dermatitis
Leung, D. Y. M. (2016) · Current Opinion in Pediatrics · doi:10.1097/mop.0000000000000374 · Cited by 44
Esaki, H., Czarnowicki, T., Gonzalez, J., Oliva, M., Talasila, S., Haugh, I. M., Rodriguez, G., Becker, L., Krueger, J. G., Guttman‐Yassky, E., et al. (2016) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2016.04.052 · Cited by 44
Self-citationČelakovská, J., Ettlerová, K., Ettler, K., Vaněčková, J., & Bukač, J. (2014) · Journal of the European Academy of Dermatology and Venereology · doi:10.1111/jdv.12891 · Cited by 40
Hoffjan, S., & Stemmler, S. (2015) · Archives of Dermatological Research · doi:10.1007/s00403-015-1550-6 · Cited by 38
Björkander, S., Hell, L., Johansson, M. A., Forsberg, M. M., Lasaviciute, G., Roos, S., Holmlund, U., & Sverremark‐Ekström, E. (2016) · Scientific Reports · doi:10.1038/srep22083 · Cited by 36
Kwon, Y. S., Oh, S. H., Wu, W. H., Bae, B. G., Lee, H. J., Lee, M., & Lee, K. H. (2009) · Experimental Dermatology · doi:10.1111/j.1600-0625.2009.00971.x · Cited by 34
Atopic dermatitis keratinocytes exhibit normal TH17 cytokine responses
Nograles, K. E., Suárez‐Fariñas, M., Shemer, A., Fuentes‐Duculan, J., Chiricozzi, A., Cardinale, I. R., Zaba, L. C., Kikuchi, T., Ramon, M., Bergman, R., et al. (2010) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2009.12.934 · Cited by 33
Self-citationIL-17 promotes keratinocyte proliferation via the downregulation of C/EBPα
Ma, W., JIA, K., & Zhang, Y. (2015) · Experimental and Therapeutic Medicine · doi:10.3892/etm.2015.2939 · Cited by 32
An association of periostin levels with the severity and chronicity of atopic dermatitis in children
Sung, M., Lee, K. S., Ha, E. K., Lee, S. J., Kim, M. A., Lee, S. W., Jee, H. M., Sheen, Y. H., Jung, Y. H., & Han, M. Y. (2017) · Pediatric Allergy and Immunology · doi:10.1111/pai.12744 · Cited by 31
Exploring CCL18, eczema severity and atopy
Hon, K. E., Ching, G. K., Ng, P. C., & Leung, T. F. (2011) · Pediatric Allergy and Immunology · doi:10.1111/j.1399-3038.2011.01174.x · Cited by 29
Monitoring of serologic immune parameters in inflammatory skin diseases
Gebhardt, M., Wenzel, H. C., Hipler, U. ‐., Herrmann, D. B. J., & Wollina, U. (1997) · Allergy · doi:10.1111/j.1398-9995.1997.tb00180.x · Cited by 29
Lucae, S., Schmid‐Grendelmeier, P., Wüthrich, B., Kraft, D., Valenta, R., & Linhart, B. (2015) · Allergy · doi:10.1111/all.12711 · Cited by 26
Donetti, E., Cornaghi, L., Arnaboldi, F., Landoni, F., Romagnoli, P., Mastroianni, N., Pescitelli, L., Preis, F. W. B., & Prignano, F. (2016) · Experimental Cell Research · doi:10.1016/j.yexcr.2016.05.004 · Cited by 21
Wollenberg, A., Howell, M. D., Guttman‐Yassky, E., Silverberg, J. I., Birrell, C. E., Kell, C., Ranade, K., Dawson, M., & van der Merwe, R. (2018) · SKIN The Journal of Cutaneous Medicine · doi:10.25251/skin.2.supp.28 · Cited by 18
Self-citation
Cited by
Atopic dermatitis endotypes and implications for targeted therapeutics
Czarnowicki, T., He, H., Krueger, J. G., & Guttman-Yassky, E. (2019) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2018.10.032 · Cited by 631
Self-citationType 2 immunity in the skin and lungs
Akdis, C. A., Arkwright, P. D., Brüggen, M.-C., Busse, W., Gadina, M., Guttman‐Yassky, E., Kabashima, K., Mitamura, Y., Vian, L., Wu, J., et al. (2020) · Allergy · doi:10.1111/all.14318 · Cited by 560
Self-citationSimpson, E. L., Paller, A. S., Siegfried, E. C., Boguniewicz, M., Sher, L., Gooderham, M. J., Beck, L. A., Guttman-Yassky, E., Pariser, D., Blauvelt, A., et al. (2020) · JAMA Dermatology · doi:10.1001/jamadermatol.2019.3336 · Cited by 524
Self-citationHarb, H., & Chatila, T. A. (2020) · Clinical & Experimental Allergy · doi:10.1111/cea.13491 · Cited by 518
Abrocitinib versus Placebo or Dupilumab for Atopic Dermatitis
Bieber, T., Simpson, E. L., Silverberg, J. I., Thaçi, D., Paul, C., Pink, A. E., Kataoka, Y., Chu, C.-Y., DiBonaventura, M., Rojo, R., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2019380 · Cited by 476
Self-citation
Metadata
- Authors
- Guttman-Yassky, E., Bissonnette, R., Ungar, B., Suárez-Fariñas, M., Ardeleanu, M., Esaki, H., Suprun, M., Estrada, Y., Xu, H., Peng, X., Silverberg, J. I., Menter, A., Krueger, J. G., Zhang, R., Chaudhry, U., Swanson, B., Graham, N. M. H., Pirozzi, G., Yancopoulos, G. D., & D. Hamilton, J. D.
- Venue
- Journal of Allergy and Clinical Immunology
- Publisher
- Elsevier BV
- Published
- 2019-01
- Volume
- 143
- Issue
- 1
- Pages
- 155-172
- ISSN
- 0091-6749 (ISSN-L)
- OpenAlex
- W2892288216
- Cited by
- 697
- References
- 153
- FWCI
- 51.50
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.